BUZZ-Jiangsu Hengrui HK shares hit near 4-month peak on Bristol-Myers Squibb tie-up

Bristol-Myers Squibb

BMY

0.00

** Hong Kong shares of Jiangsu Hengrui Pharmaceuticals jump 16.2% in the second rising session to HK$76.75, their highest point since January 20

** Stock set for the biggest one-day pct gain since July 28, 2025

** Shanghai-listed shares 600276.SS surge 8.6% to 58.1 yuan, set for the biggest one-day pct gain since April 15

** China-based oncology-focused drug developer enters into collaboration and license deals with Bristol-Myers Squibb (BMS) BMY.N to advance a portfolio of 13 early-stage programs in oncology, hematology, and immunology

** BMS will pay Hengrui up to $950 million, including a $600 million upfront payment, a $175 million first anniversary payment, and a second contingent anniversary payment of $175 million in 2028

** The potential milestone payments of the agreements are up to $15.2 billion

** YTD, Shanghai-listed stock down 1.7%, while Hong Kong stock up 2.1%, Hang Seng Biotech Index .HSBIO up 2.8%

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.